TY - JOUR
T1 - Successful Living Related Kidney Transplantation Across an Anti-Donor HLA Antibody
AU - Ben-Youssef, R.
AU - Iwaki, Y.
AU - Baron, P.
AU - Franco, E.
AU - Rowsell, E.
AU - Buckert, L.
AU - Ojogho, O.
PY - 2006/6
Y1 - 2006/6
N2 - In preconditioning highly sensitized kidney transplant candidates, renal allograft outcomes have been better when the serum titer for class I anti-HLA donor-specific antibody (DSA) is low in the recipient at the time of transplantation. However, the ideal level to which the titer should be lowered is still controversial. We report a primary living related kidney transplant in a 34-year-old highly sensitized woman (pretransplant panel-reactive antibody = 70%) with end-stage renal disease secondary to chronic glomerulonephritis. We sought to desensitize by lowering the DSA titer specifically to 1:4 pretransplant. A standard complement-dependent cytotoxicity cross-match with her donor (sister) was repeatedly negative, although she was positive for class I antibody against her mismatched HLA antigen (A*2402) at a titer up to 1:16 by the single-antigen flowbead assay. The target DSA titer of 1:4 before transplant was achieved by 12 sessions of plasmapheresis (PP) over 7 weeks, plus two intravenous immune globulin infusions (IVIG) (500 mg/kg/infusion). The patient outcome was excellent. Neither IVIG nor PP was needed posttransplant. The serum creatinine ranged between 0.5 mg/dL and 1.2 mg/dL, and no rejection episode was documented at 28 weeks posttransplant. Therefore, we encourage the use of IVIG and PP to lower the DSA titer to at least 1:4 before kidney transplantation in highly sensitized patients. Large prospective trials are needed to establish a consensus for pretransplant risk assignment and to evaluate the need for desensitization. © 2006 Elsevier Inc. All rights reserved.
AB - In preconditioning highly sensitized kidney transplant candidates, renal allograft outcomes have been better when the serum titer for class I anti-HLA donor-specific antibody (DSA) is low in the recipient at the time of transplantation. However, the ideal level to which the titer should be lowered is still controversial. We report a primary living related kidney transplant in a 34-year-old highly sensitized woman (pretransplant panel-reactive antibody = 70%) with end-stage renal disease secondary to chronic glomerulonephritis. We sought to desensitize by lowering the DSA titer specifically to 1:4 pretransplant. A standard complement-dependent cytotoxicity cross-match with her donor (sister) was repeatedly negative, although she was positive for class I antibody against her mismatched HLA antigen (A*2402) at a titer up to 1:16 by the single-antigen flowbead assay. The target DSA titer of 1:4 before transplant was achieved by 12 sessions of plasmapheresis (PP) over 7 weeks, plus two intravenous immune globulin infusions (IVIG) (500 mg/kg/infusion). The patient outcome was excellent. Neither IVIG nor PP was needed posttransplant. The serum creatinine ranged between 0.5 mg/dL and 1.2 mg/dL, and no rejection episode was documented at 28 weeks posttransplant. Therefore, we encourage the use of IVIG and PP to lower the DSA titer to at least 1:4 before kidney transplantation in highly sensitized patients. Large prospective trials are needed to establish a consensus for pretransplant risk assignment and to evaluate the need for desensitization. © 2006 Elsevier Inc. All rights reserved.
KW - Kidney Failure, Chronic/etiology
KW - Histocompatibility Testing
KW - Humans
KW - Treatment Outcome
KW - Living Donors
KW - Pregnancy
KW - Flow Cytometry
KW - Kidney Transplantation/immunology
KW - Pregnancy Complications/surgery
KW - Glomerulonephritis/complications
KW - Adult
KW - Family
KW - Female
KW - Renal Dialysis
UR - http://www.scopus.com/inward/record.url?scp=33745186420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745186420&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/d8695cf5-a9a3-3e7c-8c50-5a4e4420ca19/
U2 - 10.1016/j.transproceed.2006.03.021
DO - 10.1016/j.transproceed.2006.03.021
M3 - Article
C2 - 16797281
SN - 0041-1345
VL - 38
SP - 1280
EP - 1282
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 5
ER -